Kyowa Hakko Kogyo Co., Ltd.

Shizuoka Prefectural University Corporation

Ricoh Company, Ltd.

Ishihara Sangyo Kaisha, Ltd.

Kyowa Hakko Kogyo

Sony Corporation

Hideyuki Sato

Etsuo Ohshima

Hiroyuki Obase

Tetsuji Ohno

Fumihiko Kanai

Toshiaki Kumazawa

Tomoko Ishikawa

Shiho Takahara

Koji Yamada

Satomi Onoue

Yoshinari Higuchi

Tatsuru Moritani

Shuji Okegawa

Tadahiko Morinaga

Hiroyuki Arakawa

Yoshiki Seto

Takeshi Shindo

The present invention provides a composition which effectively enhances the stability of N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof in a liquid composition. More specifically, the present invention provides a liquid composition comprising N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexanecarboxamide or a salt thereof, a water-soluble additive and water.

Pharmaceutical composition with excellent storage stability

A method for producing particles, the method including: applying vibration to a liquid including a physiologically active substance and included in a liquid-column resonance liquid-chamber to form a standing wave based on liquid column resonance, to thereby discharge the liquid from at least one discharging port, which is formed in an amplitude direction of the standing wave, to at least one region corresponding to at least one anti-node of the standing wave; and drying the liquid discharged, to thereby form particles.

Method for producing particles

A tricyclic compound represented by the following formula (I): ##STR1## exhibits antagonism to angiotensin II receptors.

Tricyclic compounds on angiotensin II receptor antagonists

A tricyclic compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen or lower alkyl; A represents cyano, carboxyl, tetrazolyl, cyano-substituted phenyl, carboxyl-substituted phenyl or tetrazolyl-substituted phenyl; V represents --(CH.sub.2).sub.m --(wherein m is an integer of 0 to 2); W represents ##STR2## (wherein R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, halogen, lower alkyl, cycloalkyl, halogenated lower alkyl, hydroxy, lower alkoxy, amino, lower alkylamino, carboxyl or lower alkoxycarbonyl; and Q.sup.1 --Q.sup.2 --Q.sup.3 --Q.sup.4 represents N.dbd.CH--CH.dbd.CH; X.sup.1 --X.sup.2 --X.sup.3 represents CH.dbd.CH--CH.dbd.CH, S--CH.dbd.CH or CH.dbd.CH--S; Y represents a single bond, CH.sub.2, O, S, CH.sub.2 O, OCH.sub.2, CH.sub.2 S, SCH.sub.2, CH.sub.2 CH.sub.2 or CH.dbd.CH; and Z.sup.1 --Z.sup.2 represents C.dbd.CH, CH--CH.sub.2 or CH--CH(COOH)-- or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits antagonism to angiotensin II receptors.

Tricyclic compounds

A tricyclic compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen or lower alkyl; A represents cyano, carboxyl, tetrazolyl, cyano-substituted phenyl, carboxyl-substituted phenyl or tetrazolyl-substituted phenyl; V represents --(CH.sub.2).sub.m -- wherein m is an integer of 0 to 2; W represents ##STR2## and Q.sup.1 --Q.sup.2 --Q.sup.3 --Q.sup.4 represents N.dbd.CH--CH.dbd.CH, CH.dbd.CH--CH.dbd.CH or CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2, ##STR3## and Q represents N or CH; X.sup.1 --X.sup.2 --X.sup.3 represents CH.dbd.CH--CH.dbd.CH, S--CH.dbd.CH or CH.dbd.CH--S; Y represents CH.sub.2 CH.sub.2 ; and Z.sup.1 --Z.sup.2 represents N--(CH.sub.2).sub.n -- wherein n is an integer of 1 to 3 or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Shizuoka, Japan

Hideyuki Sato